Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

As of February 6, 2023, the average one-year price target for Axonics Modulation Technologies is $85.23. The forecasts range from a low of $65.65 to a high of $105.00. The average price target ...

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) on October 8 and set a price target of $71.00. The company’s shares closed ...

As of January 31, 2023, the average one-year price target for Axonics Modulation Technologies is $85.23. The forecasts range from a low of $65.65 to a high of $105.00. The average price target ...

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating ...

As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. The ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Sacral neuromodulation may not work for everyone, but Axonics is hoping to more accurately identify those who may indeed be good candidates for the technology. The devicemaker has acquired a new ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Monday reported third-quarter net income of $3.9 million, after reporting a loss in the same period a year ...